The U.S. Food & Drug Administration (FDA) approves ribociclib, sold as Kisqali, in combination with another drug, NSAI, for some forms of early high-risk breast cancer after the drug showed in tests a statistically significant improvement in patients.
related: #cancer #drug
Contact: info(@)neat-news(dot)com.
neat-news.com is not responsible for the content of external sites.
We do not link to external sites in return for money or any other benefits.
Note that photos are usually stock photos, mostly taken from
Wikipedia, which we can use royalty-free either since they are in
the public domain or available under an open licence such as
a share alike licence.
The page is maintained in Germany and for any legal matters the
laws of Germany apply.
Any warranty or liability is excluded in the widest legally
possible sense.
© neat-news.com 2016-2025.
